Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Grapefruit Benefits

Cardium Presents Gene Activated Matrix Technology And Update On Excellarate Clinical Development Program At ASGT Annual Meeting
Cardium Therapeutics (NYSE Amex: CXM) and its subsidiary Tissue Repair Company (TRC) announced a presentation entitled "Phase 2b Study of GAM501 (Ad5PDGF-B/Collagen) in the Treatment of Diabetic Ulcers" at the Late Stage Industry Clinical Trials Symposium at the American Society of Gene Therapy (ASGT) Annual meeting in San Diego, California, on May 27, 2009. Dr. Barbara K. Sosnowski, Cardium"s Vice President of Biologics Development and the Chief Operating Officer of Cardium"s Tissue Repair Company Operating Unit, provided an update on TRC"s Phase 2b MATRIX clinical trial and the new formulation of the Excellarate(TM) product candidate, as well as an overview of the prior clinical study of Excellarate.
generic viagra online
Reform Questions Continue To Loom
Reuters reports that "President Barack Obama"s drive to overhaul the U.S. healthcare system may be back on track thanks to Senate efforts to cut the price tag to $1 trillion, but a bipartisan deal on the sweeping proposal still is far from certain ... Senate Finance Committee Chairman Max Baucus was upbeat last week after announcing that panel members had found ways to bring the price tag to about $1 trillion over 10 years, down from an earlier estimate of a staggering $1.6 trillion ... Instead, the core group of negotiators -- three Democrats and four Republicans -- issued a tepid statement on Thursday merely affirming their commitment to continue negotiations."
News of the day
Navigation In Hip Resurfacing
Hip resurfacing can be a good alternative to total hip replacement (THR) in young adults because it conserves bone and it has acceptable short- to medium-term results. However, there have been concerns about fractures of the femoral neck with this procedure, partly due to notching and varus alignment during implantation.
Mental Health

Study Finds Cancer Is The Second Most Frequent Cause Of Death In Individuals With Schizophrenia

People with schizophrenia are four times as likely to die from all causes and are 50 percent more likely to die from cancer compared to people in the general population. That is the conclusion of a new study published in the August 1, 2009 issue of CANCER, a peer-reviewed journal of the American Cancer Society. The study"s results suggest that extra efforts should be made to improve cancer prevention and early detection in patients with schizophrenia. Schizophrenia is associated with an increased incidence of premature death, in part due to a high rate of suicide among individuals with the disease. However, suicide alone does not account for the shortened life expectancy seen in schizophrenia patients. Some studies have indicated that cancer mortality may play a role, but other data suggest that cancer rates are actually lower among individuals with schizophrenia compared with the general population. To more precisely determine the prevalence of cancer in patients with schizophrenia, Prof. Frédéric Limosin of the University of Reims, Robert Debré Hospital, in Reims, France and colleagues prospectively studied 3,470 patients with schizophrenia and tracked cancer incidence beginning in 1993. The investigators also sought to identify characteristics that might help predict which schizophrenic patients are likely to develop cancer. The researchers found that 476 (14%) patients died during the eleven years of the study, a death rate was nearly four-fold higher than in the general population. Seventy-four patients died of cancer, making it the second most frequent cause of death behind suicide. In men with schizophrenia, the risk of death due to lung cancer was significantly higher than that in the general population, but the risk of overall cancer death was not significantly higher. In women, the risk of overall mortality was significantly higher than among the general population. The proportion of patients who were smokers was significantly higher in the study population than in the general population (56.3 vs. 33.0%). In female schizophrenic patients, the risk of death due to breast cancer was significantly higher than in the general population. The authors say possible explanations include is a delay in diagnosis due to patients paying less attention to symptoms; the difficulty for schizophrenic patients to benefit from optimum treatment; and less compliance to treatment. Prof. Limosin and his collaborators noted that additional studies should further examine cancer rates in individuals with schizophrenia and should better define the characteristics of tumors that arise in these patients. Notes> Article: "Cancer mortality in patients with schizophrenia: 11-year prospective cohort study." Eric Tran, Frédéric Rouillon, Jean-Yves Loze, FranÃýoise Casadebaig, Alain Philippe, Fabien Vitry, and Frédéric Limosin. CANCER; Published Online: June 22, 2009 (DOI: 10.1002/cncr.24383); Print Issue Date: August 01, 2009. The information contained in this release is protected by copyright. Free abstracts of these articles will be available via the CANCER News Room upon online publication. Claire Greenwell American Cancer Society


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009